Anixa Biosciences, Inc. (ANIX)

Anixa Biosciences, Inc. (ANIX) Healthcare & Pipeline Overview

Anixa Biosciences, Inc. is a biotechnology company developing innovative therapies and vaccines, primarily focused on addressing unmet needs in oncology and infectious diseases. Their pipeline features novel CAR-T technology targeting ovarian cancer and vaccines designed to prevent triple-negative breast and ovarian cancers, positioning them in the competitive biotechnology landscape.

What Is the Investment Thesis for ANIX?

Anixa Biosciences presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on innovative CAR-T technology for ovarian cancer and vaccines for triple-negative breast and ovarian cancer addresses significant unmet medical needs. Key value drivers include successful clinical trial outcomes and potential partnerships for commercialization. Upcoming catalysts include progress in clinical trials for its CAR-T therapy and vaccine candidates. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional funding, given the company's small market capitalization of $105.64M and limited employee count.

Based on FMP financials and quantitative analysis

ANIX Key Highlights

• Anixa Biosciences is focused on developing therapies and vaccines for unmet needs in oncology and infectious diseases.
• The company's therapeutics programs include CAR-T technology for ovarian cancer.
• Anixa is developing vaccines for triple negative breast cancer and ovarian cancer.
• The company collaborates with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19.
• Anixa Biosciences changed its name from ITUS Corporation in October 2018.

Who Are ANIX's Competitors?

ANIX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ANIX's Key Strengths?

• Innovative CAR-T technology for ovarian cancer.
• Vaccine programs targeting unmet needs in oncology.
• Collaboration with MolGenie GmbH for anti-viral drug development.
• Experienced management team focused on oncology and infectious diseases.

What Are ANIX's Weaknesses?

• Limited financial resources and small market capitalization.
• Dependence on successful clinical trial outcomes.
• Early-stage development programs with significant regulatory risk.
• Small number of employees.

What Could Drive ANIX Stock Higher?

• Clinical trial results for ovarian cancer CAR-T therapy.
• Progress in the development of vaccines for triple-negative breast and ovarian cancer.
• Collaboration with MolGenie GmbH for anti-viral drug development.
• Potential partnerships and collaborations with larger pharmaceutical companies.

What Are the Key Risks for ANIX?

• Negative return on equity (-65.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures and regulatory setbacks.
• Competition from larger pharmaceutical companies.
• Need for additional funding and potential dilution.
• Patent expiration and intellectual property challenges.

What Are the Growth Opportunities for ANIX?

• Expansion of CAR-T Technology: Anixa has an opportunity to expand its CAR-T technology beyond ovarian cancer to other solid tumors. The global CAR-T cell therapy market is projected to reach $10.89 billion by 2032, growing at a CAGR of 22.7% from 2023. This expansion could significantly increase Anixa's market potential, provided they can demonstrate efficacy and safety in additional indications. Timeline for expansion is dependent on clinical trial results, with initial studies potentially beginning within the next 2-3 years.
• Development of Preventative Vaccines: Anixa's development of preventative vaccines against ovarian and triple-negative breast cancer represents a significant growth opportunity. The market for cancer vaccines is expected to reach $13.5 billion by 2030. Success in this area would position Anixa as a leader in cancer prevention. Clinical trials are ongoing, with potential for initial efficacy data within the next 1-2 years.
• Partnerships and Collaborations: Anixa can leverage partnerships and collaborations to accelerate the development and commercialization of its therapies and vaccines. Collaborating with larger pharmaceutical companies could provide access to funding, expertise, and distribution networks. The timeline for securing such partnerships is uncertain, but ongoing discussions are likely, with potential for announcements within the next year.
• Expansion of Anti-Viral Drug Pipeline: Anixa's collaboration with MolGenie GmbH to develop anti-viral drug candidates against COVID-19 could lead to the expansion of its pipeline into other infectious diseases. The global anti-viral drug market is expected to grow to $64.8 billion by 2027. This expansion could diversify Anixa's revenue streams and reduce its reliance on oncology. Development timelines are dependent on research progress and regulatory approvals, with potential for new candidates entering clinical trials within the next 2-3 years.
• Geographic Expansion: Anixa has the opportunity to expand its geographic reach beyond the United States. The global market for cancer therapies and vaccines is growing rapidly, particularly in emerging markets. Expanding into these markets could significantly increase Anixa's revenue potential. The timeline for geographic expansion is dependent on regulatory approvals and partnerships, with potential for initial expansion into Europe or Asia within the next 3-5 years.

What Opportunities Does ANIX Have?

• Expansion of CAR-T technology to other solid tumors.
• Development of preventative vaccines for other cancers.
• Partnerships and collaborations with larger pharmaceutical companies.
• Expansion into new geographic markets.

What Threats Does ANIX Face?

• Clinical trial failures and regulatory setbacks.
• Competition from larger pharmaceutical companies.
• Need for additional funding and potential dilution.
• Patent expiration and intellectual property challenges.

What Are ANIX's Competitive Advantages?

• Proprietary CAR-T technology for ovarian cancer.
• Vaccine development programs targeting unmet needs.
• Collaboration with MolGenie GmbH for anti-viral drug development.

What Does ANIX Do?

Anixa Biosciences, Inc., founded in 1982 and formerly known as ITUS Corporation until its name change in October 2018, is a biotechnology company headquartered in San Jose, California. The company is dedicated to developing therapies and vaccines that address critical unmet needs in oncology and infectious diseases. Anixa's therapeutic programs are centered around the development of a chimeric endocrine receptor T-cell technology, a novel approach to chimeric antigen receptor T-cell (CAR-T) technology specifically designed for the treatment of ovarian cancer. Additionally, Anixa is engaged in the discovery and development of anti-viral drug candidates aimed at treating COVID-19 by inhibiting specific protein functions of the virus. On the vaccine front, Anixa is developing a vaccine against triple-negative breast cancer, a particularly aggressive form of the disease, and a preventative vaccine against ovarian cancer. The company is also exploring the development of immuno-therapy drugs targeting various forms of cancer. Anixa Biosciences collaborates with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19, leveraging external expertise to accelerate its research and development efforts. Anixa's strategic focus on innovative technologies and unmet medical needs aims to create significant value in the healthcare sector.

What Products and Services Does ANIX Offer?

• Develops CAR-T technology for the treatment of ovarian cancer.
• Discovers and develops anti-viral drug candidates for the treatment of COVID-19.
• Develops a vaccine against triple negative breast cancer.
• Develops a preventative vaccine against ovarian cancer.
• Develops immuno-therapy drugs against cancer.
• Collaborates with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19.

How Does ANIX Make Money?

• Focuses on research and development of therapies and vaccines.
• Seeks to out-license or partner its technologies for commercialization.
• Generates revenue through collaborations and potential future product sales.

What Industry Does ANIX Operate In?

Anixa Biosciences operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and significant regulatory oversight. The company's focus on oncology and infectious diseases aligns with major market trends, as these areas represent substantial unmet medical needs and significant commercial opportunities. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share with innovative therapies and vaccines. Anixa's success will depend on its ability to navigate the complex regulatory environment, secure funding, and demonstrate clinical efficacy in its key programs.

Who Are ANIX's Key Customers?

• Patients with ovarian cancer.
• Patients at risk of triple negative breast cancer.
• Patients at risk of ovarian cancer.
• Potential pharmaceutical partners.

FY2026 estForward Outlook

Wall Street analysts project Anixa Biosciences, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.33.

F-Score 2/9Financial Health

Anixa Biosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 15.31 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -66%Key Financial Metrics

Return on equity for Anixa Biosciences, Inc. stands at -65.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -67.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.5%, the inverse of the P/E and a quick read on earnings relative to price.

Anixa Biosciences, Inc. (ANIX) Valuation Context

Valued at $105.64M, ANIX is classified as a micro-cap stock. Relative to its peer group, ANIX's quantitative score of 54/100 is below the peer average of 79/100.

Company Profile

Anixa Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Jose, US. The company is led by CEO Amit Kumar. ANIX has traded publicly since 1983.

ANIX Financials

ANIX Latest News

ANIX Analyst Consensus

ANIX MoonshotScore

Common Questions About ANIX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources